TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12612157
Drug: Control foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control foods (similar to treatment but without TOP and beta-glucan)
Study: 12612157
Drug: TOP/beta-glucan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP/beta-glucan treatment
Study: 7313578
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of ampicillin
Study: 7313578
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of ampicillin
Study: 7313578
Drug: Both IM
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IM and IV administration of ampicillin
Study: 19489429
Drug: Individual reminiscence
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual reminiscence therapy (5-6 weekly sessions, 30-60 minutes each)
Study: 15483468
Drug: Recombinant gp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant gp120 HIV vaccine (AIDSVAX B/B)
Study: 11213870
Drug: Abalon (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abalon (soy protein [50 g/day] with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day])
Study: 11213870
Drug: Placebo (casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (casein [50 g/day] and cellulose [20 g/day])
Study: 2802549
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (1,000 mg single dose)
Study: 2802549
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg three times a day for 7 days)
Study: 28381506
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIg) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months
Study: 28381506
Drug: Placebo (low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (low‐dose albumin)
Study: 19366272
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg/day (with option to adjust to 5 or 10 mg/day at weeks 4 and 8)
Study: 19366272
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg/day (pre-washout)
Study: 19366272
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (post-washout)
Study: 9069297
Drug: Sucralfate plus
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate plus antacid, diphenhydramine, and viscous lidocaine
Study: 9069297
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination of antacid, diphenhydramine, and viscous lidocaine
Study: 8366411
Drug: Amoxicillin/clavulanate potassium
Normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium for 10 days
Study: 30010081
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMFs) treatment (50 min/session, 6 sessions/week, total of 25 sessions)
Study: 25092690
Drug: Nemonoxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (250 to 750 mg)
Study: 25092690
Drug: Nemonoxacin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin (maximum dose 1,250 mg)
Study: 18478914
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + NPPV
Study: 9591438
Drug: Eosinophil cationic
Normalized name: Eosinophil cationic protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil cationic protein (ECP) evaluation before, during, and after immunotherapy with pollen or mite allergens (Allergovit or Novo‐Helisen, Nexter, Allergopharma)
Study: 9591438
Drug: ECP levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP levels during immunotherapy
Study: 7887824
Drug: 2-hour hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour hemodialysis at high blood flow (400 ml/min)
Study: 7887824
Drug: 4-hour hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour hemodialysis at low blood flow (200 ml/min)
Study: 3348136
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) sublingual tablets
Study: 28678044
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for gastrointestinal risk factors and prophylactic proton pump inhibitor (PPI) therapy (pantoprazole 40 mg for 1 year)
Study: 28678044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no screening or PPI therapy)
Study: 26431854
Drug: TII SCB
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TII SCB (16 mL of lidocaine 1.5% with epinephrine 5 µg·mL(‐1) into the largest neural cluster and additional 16 mL divided into equal aliquots injected inside each satellite cluster)
Study: 26431854
Drug: AXB (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXB (5.5 mL around the musculocutaneous nerve and 23.5 mL at the 6 o'clock position of the axillary artery)
Study: 23719518
Drug: Nontherapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontherapeutic dose of intermittent ultrasound on the affected side
Study: 17630036
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin)
Study: 17630036
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (capecitabine, irinotecan, and capecitabine plus oxaliplatin)
Study: 15450049
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) oral suspension 800 mg/d for 12 weeks
Study: 9715363
Drug: Clomipramine (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (open maintenance treatment)
Study: 8071282
Drug: Dothiepin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (150 mg nightly)
Study: 8071282
Drug: Doxepin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (150 mg nightly)
Study: 786358
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of phenytoin sodium at 12.00 hours
Study: 786358
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three spaced doses of phenytoin sodium/day
Study: 28551844
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg on day 1 followed by 100 mg twice daily
Study: 21967830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physician and group incentives
Study: 19757980
Drug: Acupressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure therapy (AT)
Study: 17694378
Drug: Combined intraarterial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intraarterial and intramuscular transplantation of autologous mononuclear bone marrow stem cells
Study: 15093755
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel antagonists (nifedipine or nicardipine)
Study: 11367652
Drug: Tripterygium Wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium Wilfordii Complex Ester Tablet (TWT), 2 tablets, 3 times a day for 6 weeks
Study: 11367652
Drug: Tripterygium Wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium Wilfordii Polycoside Tablet (TPT), 2 tablets, 3 times a day for 6 weeks
Study: 11367652
Drug: Tripterygium Wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium Wilfordii Complex Ester Tablet (TWT)
Study: 11367652
Drug: Tripterygium Wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium Wilfordii Polycoside Tablet (TPT)
Study: 7889947
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg single intravenous dose)
Study: 7889947
Drug: Cefamandole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (2 g before and 1 g after surgery)
Study: 26847031
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support group attendance (8 weekly sessions of 2 hours each)
Study: 19274316
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg (1 ml) of morphine diluted in 9 ml of saline
Study: 19274316
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg (10 ml) of 0.25% bupivacaine without epinephrine
Study: 8882904
Drug: V0.1-rest in
Approvals — FDA: no, EMA: no, PMDA: no
Description: V0.1-rest in normal subjects (Nor: 0.25 +/- 0.10 l/s), CPE (0.27 +/- 0.06 l/s), IP (0.26 +/- 0.06 l/s)
Study: 8882904
Drug: V0.1-max in
Approvals — FDA: no, EMA: no, PMDA: no
Description: V0.1-max in normal subjects (Nor: 3.66 +/- 1.16 l/s), CPE (0.82 +/- 0.25 l/s), IP (1.02 +/- 0.21 l/s)
Study: 3884032
Drug: Conventional superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional superficial X-ray therapy (300 rad, 3 Gy)
Study: 3884032
Drug: Grenz ray
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz ray therapy (900 rad, 9 Gy)
Study: 22017365
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite extract for 2 years
Study: 22017365
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) and Placebo
Study: 20636999
Drug: Cream B
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream B (cosmetic emulsion with active ingredients: soy and jasmine)
Study: 20636999
Drug: Cream A
Normalized name: KIT, CREAM AND GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream A (vehicle without active ingredients)
Study: 18569241
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of computer programs and teacher-led presentation
Study: 16055571
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly relaxation and focus group discussions)
Study: 12448352
Drug: Inhaled capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled capsaicin (0.4 mumol/L)
Study: 12448352
Drug: Inhaled capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled capsaicin (2 mumol/L)
Study: 12448352
Drug: Inhaled capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled capsaicin (10 mumol/L)
Study: 10598433
Drug: Intraarticular morphine/bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine/bupivacaine (25 ml of 0.25% bupivacaine and 2 mg of morphine)
Study: 10598433
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diclofenac i.m. (75 mg) and intraarticular morphine/bupivacaine
Study: 10598433
Drug: Diclofenac i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac i.m. (75 mg)
Study: 1752623
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day long acting sustained release isosorbide dinitrate (SRISDN)
Study: 1752623
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily short acting isosorbide dinitrate
Study: 7091638
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg domperidone
Study: 7091638
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antiemetic medication (control group)
Study: 27875287
Drug: Standard-dose AAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose AAs (2.4 g/[kg·d]) and SOY (n = 24)
Study: 27875287
Drug: Standard-dose AAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose AAs (2.4 g/[kg·d]) and MIX (n = 25)
Study: 27875287
Drug: High-dose AAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AAs (3.6 g/[kg·d]) and SOY (n = 24)
Study: 27875287
Drug: High-dose AAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AAs (3.6 g/[kg·d]) and MIX (n = 23)
Study: 17494885
Drug: Uptitration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitration of benazepril (median 20 mg/d; range 10 to 40)
Study: 17494885
Drug: Uptitration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitration of losartan (median 100 mg/d; range 50 to 200)
Study: 17494885
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage of benazepril (10 mg/d)
Study: 17494885
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage of losartan (50 mg/d)
Study: 11804989
Drug: Nicorandil (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (an agonist of K(ATP) channels)
Study: 11804989
Drug: Glibenclamide (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (an antagonist of K(ATP) channels)
Study: 103358
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg x 3-4 per day, starting 1-2 days before menstruation
Study: 103358
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg x 3-4 per day, starting on the first day of bleeding
Study: 31959202
Drug: BCAA-based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-based supplement (13.2g carbohydrates; 3.2g BCAA; 1.6g L-alanine per dose)
Study: 31959202
Drug: BCAA-based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-based supplement
Study: 24989842
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (14,000 units once weekly for 6 weeks)
Study: 22164761
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day Lentinex for 6 weeks
Study: 22164761
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day Lentinex
Study: 19673020
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose midazolam in combination with meperidine (Group A)
Study: 19673020
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose midazolam in combination with meperidine (Group B)
Study: 16771948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Study: 16771948
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Study: 16771948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Study: 16771948
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Study: 16771948
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose pegylated interferon alpha-2b + ribavirin for genotype 1
Study: 16771948
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pegylated interferon alpha-2b + ribavirin for genotype 1
Study: 16771948
Drug: Doses exceeding
Normalized name: Agents for dermatitis, excluding corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses exceeding the 1-2-5 threshold for genotype 1
Study: 15596921
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further brain treatment (n = 46 patients)
Study: 9848882
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol and 2.5 mg medroxyprogesterone (n=7)
Study: 9848882
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol alone (n=8)
Study: 8119527
Drug: Proximal duodenal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal duodenal distention (10, 20, 30 mL of air) during fasting
Study: 8119527
Drug: Distal duodenal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal duodenal distention (10, 20, 30 mL of air) during fasting
Study: 8119527
Drug: Proximal duodenal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal duodenal distention (10, 20, 30 mL of air) postprandially
Study: 8119527
Drug: Distal duodenal
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal duodenal distention (10, 20, 30 mL of air) postprandially
Study: 2680866
Drug: alpha-interferon therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon therapy (90 million units per m2 total dose over 12 weeks)
Study: 336652
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pentobarbital
Study: 336652
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg methyprylon
Study: 336652
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg glutethimide
Study: 28661970
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection + postresuscitation care bundle
Study: 26836793
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg daily)
Study: 19804594
Drug: Topical nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nicotinamide (0.2% or 5%)
Study: 16735702
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy containing one course with standard dose and one course with high-dose cytarabine
Study: 16735702
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy containing two courses with high-dose cytarabine
Study: 16735702
Drug: Postremission therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postremission therapy by prolonged maintenance
Study: 16735702
Drug: Postremission therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postremission therapy by busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation
Study: 16735702
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy and postremission therapy
Study: 11292473
Drug: Outpatient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient group (self-administered misoprostol)
Study: 11292473
Drug: Inpatient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient group (administered misoprostol in hospital)
Study: 9123740
Drug: Nadir PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadir PSA ≤ 0.1 ng/mL
Study: 9123740
Drug: Nadir PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadir PSA > 0.1 ng/mL
Study: 27539689
Drug: DAPT to
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT to monotherapy switch
Study: 27539689
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy after PCI
Study: 23540665
Drug: Clopidogrel combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel combined with warfarin
Study: 25401715
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 to 40 mg/d)
Study: 15061996
Drug: New method
Approvals — FDA: no, EMA: no, PMDA: no
Description: New method of arsenic trioxide administration (0.16 mg/kg divided into two doses, diluted in 250 ml of 5% glucose, given twice daily by intravenous infusion at 8 drops/min with a 2-3 hour interval)
Study: 15061996
Drug: Routine method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine method of arsenic trioxide administration (0.16 mg/kg infused intravenously once a day for at most 2 hours)
Study: 2543283
Drug: R61837, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: R61837, given by intranasal spray six times a day, total dose 25 mg, starting 28 hours before virus challenge, continued for 4 days.
Study: 2543283
Drug: R61837, total
Approvals — FDA: no, EMA: no, PMDA: no
Description: R61837, total dose 36 mg, starting 4 hours before virus challenge, continued for 6 days.
Study: 2543283
Drug: R61837, intranasal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R61837, intranasal, doses of up to 15 mg/day, given shortly after onset of symptoms.
Study: 24666170
Drug: Plasma treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma treatment (PlasmaDerm® VU‐2010) 3× per week for 8 weeks